Updated Report on Trends in Global PD-1/PD-L1 Immunotherapy Clinical Development from the Cancer Research Institute Published in Nature Reviews Drug Discovery

Latest analysis of the global PD-1/PD-L1 immunotherapy clinical development pipeline reveals dramatic growth over past two years in number of trials, drug combinations, and drug targets, but lower patient recruitment rates in the U.S. compared to China.

Read more